GENE ONLINE|News &
Opinion
Blog

2019-10-04| R&DTrials & Approvals

Novartis Reports Trial Successes of its Asthma Drugs that Holds Potential Edge Over Longstanding Market Leader

by Rajaneesh K. Gopinath
Share To

By Rajaneesh K. Gopinath, Ph.D.

The Swiss drug maker announced positive results from studies belonging to its PLATINUM Clinical Development Program that tested two inhalable asthma drug candidates. The drugs demonstrated improvement in lung function in patients who remained uncontrolled following the standard combination therapy of long-acting beta agonist and inhaled corticosteroid.

In what could be considered a double win, Novartis simultaneously announced the study results of its two-phase III trials, PALLADIUM and IRIDIUM evaluating the inhaled combinations of QVM149 and QMF149. Approval of the drugs could prove to be a major breakthrough in the field and could potentially dethrone GSK’s Advair for the treatment of asthma.

In both studies, the primary endpoint was the improvement in trough forced expiratory volume in one second (FEV1) after 26 weeks. In the PALLADIUM study, QMF149 (indacaterol acetate and mometasone furoate) met the primary endpoint by demonstrating superior improvement in lung function versus mometasone furoate. It also met the secondary endpoint, which is the improvement in the Asthma Control Questionnaire (ACQ-7) score.

On the other hand, the IRIDIUMstudy revealed that QVM149 (indacaterol acetate, glycopyrronium bromide and mometasone furoate) demonstrated a statistically significant improvement in lung function versus QMF149. While the key secondary endpoint of improvement of ACQ-7 score was not met in the IRIDIUM study, a substantial reduction was observed in severe asthma exacerbation rates with QVM149. The improvements in both studies were observed in asthma patients who remained uncontrolled following standard treatments such as inhaled corticosteroid (ICS) at medium or high dose, or low doses of Advair which is a combination of long-acting beta agonist (LABA) and ICS. Both the candidates were administered using the dose-confirming Breezhaler® device.

“Despite being on treatment with LABA/ICS, nearly half of all patients with moderate-to-severe asthma are uncontrolled and at a higher risk of exacerbations, hospitalization or even death,” said Dr. Huib Kerstjens, University Medical Center Groningen, The Netherlands. “For these patients, it is important to explore additional options to improve treatment outcomes and quality of life. The initial results of IRIDIUM show us that QVM149 can improve lung function in these patients and potentially deliver substantial reduction in exacerbation rates, which can have a significant impact on the daily lives of people with uncontrolled asthma.” Recently, Novartis’ Global Drug Development (GDD) team provided an insight into their pipeline and QVM149 was touted to be one of the 25 potential blockbusters from the company.

It is also notable that Novartis is currently evaluating another Asthma drug Fevipiprant (QAW039), an orally available antagonist of the prostaglandin D2 receptor 2. All in all, it’s an exciting year for the asthma community to look forward to.

 

References
  1. https://www.novartis.com/news/media-releases/novartis-announces-positive-results-from-phase-iii-palladium-study-inhaled-combination-qmf149-patients-uncontrolled-asthma
  2. https://www.novartis.com/news/media-releases/novartis-announces-positive-results-from-phase-iii-iridium-study-inhaled-combination-qvm149-patients-uncontrolled-asthma
  3. https://www.novartis.com/news/media-releases/novartis-highlights-company-transformation-catalyst-rich-pipeline-and-strong-progress-strategy-meet-novartis-management-investor-event

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Novartis’ Pluvicto Continues Winning Streak In Prostate Cancer Indication
2022-12-07
Novartis Shifts Gear To Phase 3 For Anti-Malaria Drug
2022-11-24
Novartis Ordered to Pay $177.8 million to Plexxikon for Patent Infringements
2022-10-03
LATEST
Relmada Blames ‘Implausible Placebo Results’ on Depression Drug’s Failure Again
2022-12-07
Using Sound Waves to Sort Blood-Based Nanoparticles
2022-12-07
Summit Bets $5 Billion On Akeso’s Bispecific Antibody
2022-12-07
Pharming announces publication of data from Phase 3 Study of leniolisib in patients with APDS in ASH's Blood
2022-12-07
Novartis’ Pluvicto Continues Winning Streak In Prostate Cancer Indication
2022-12-07
Algernon Wins FDA Orphan Drug Designation For Rare Lung Disease Candidate
2022-12-07
European Commission Continues Fight with Illumina and Orders Grail Acquisition Divestment
2022-12-07
EVENT
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2022-12-21
Avatar Medicine Forum
Online
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
2023-01-09
JPM Annual Healthcare Meeting 2023
San Francisco, USA
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!